Form 8-K OMNICELL, Inc For: Apr 21
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): April 21, 2015
OMNICELL, INC.
(Exact name of registrant as specified in its charter)
Delaware |
|
000-33043 |
|
94-3166458 |
(State or other jurisdiction of |
|
(Commission File Number) |
|
(IRS Employer |
590 E. Middlefield Road
Mountain View, CA 94043
(Address of principal executive offices, including zip code)
(650) 251-6100
(Registrants telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events.
On April 21, 2015, Omnicell International, Inc. (Omnicell International), a wholly-owned subsidiary of Omnicell, Inc., completed its acquisition of Mach 4 Automatisierungstechnik GmbH (Mach4) pursuant to the Agreement, dated February 26, 2015, by and among Apotheka Imedisa 2001 S.A., Holger Wallat, Dirk Rolf Beils and Peter Jansen (collectively, the Selling Shareholders) and Omnicell International (the Share Purchase Agreement).
Pursuant to the Share Purchase Agreement, Omnicell International purchased the entire registered share capital of Mach4 from the Selling Shareholders for aggregate consideration of approximately $16,500,000, of which $2,700,000 was placed in an escrow fund, which will ultimately be distributed to the Selling Shareholders (subject to claims that Omnicell International may have against the escrow fund for indemnification and other claims following the closing) (the Acquisition). In addition, Omnicell International will pay approximately $858,000 to Mach4 for the payoff of existing debt of Mach4. The final purchase price remains subject to certain adjustments as provided for in the Share Purchase Agreement.
A copy of the press release announcing the Acquisition is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
99.1 Press release entitled Omnicell, Inc. Closes Acquisition of Germany-based MACH4 Pharma Systems dated April 21, 2015.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
|
OMNICELL, INC. | |
|
|
|
|
|
|
Dated: April 22, 2015 |
By: |
/s/ Dan S. Johnston |
|
|
Dan S. Johnston, Executive Vice President and Chief Legal & Administrative Officer |
EXHIBIT INDEX
Exhibit Number |
|
Exhibit Title or Description |
|
|
|
99.1 |
|
Press release entitled Omnicell, Inc. Closes Acquisition of Germany-based MACH4 Pharma Systems dated April 21, 2015. |
Exhibit 99.1
For more information, contact:
Rob Seim
Chief Financial Officer
Omnicell, Inc.
800-850-6664, ext. 6478
Omnicell, Inc. Closes Acquisition of Germany-based MACH4 Pharma Systems
MACH4 a Leading Provider of Robotic Pharmacy Automation Solutions for Hospital and Retail Pharmacies
MOUNTAIN VIEW, Calif., April 21, 2015 Omnicell, Inc. (NASDAQ: OMCL), a leading provider of medication and supply management solutions to healthcare systems and pharmacies, today announced that it has completed the acquisition of MACH4 Pharma Systems, based in Bochum, Germany. MACH4s highly automated medication management systems are installed in a base of over 1,000 retail and hospital pharmacy customers primarily in Europe, with additional installations in China and the Middle East.
MACH4 Pharma Systems modular robotic solutions for dispensing medications in original manufacturers packages enables Omnicell to serve the needs of a broad spectrum of pharmacy customers, from large hospital systems to local retailers. The flexible design of MACH4 systems provides both the chaotic method of storage and retrieval that optimizes for high capacity storage in the minimum amount of physical space, and the channel method of storage and retrieval that optimizes for speed of delivery. MACH4 systems are uniquely configurable to suit each specific customers needs, and complement unique capabilities of Omnicell dispensing systems to handle medications in original manufacturers packages.
The combination of Omnicell and MACH4 is intended to create a comprehensive automated medication management offering for hospital and retail pharmacies throughout Europe and emerging markets internationally.
The addition of MACH4 Pharma Systems is an important component of Omnicells international growth strategy, said Randall Lipps, chairman, president and CEO of Omnicell. We look forward to integrating MACH4s high-volume medication management technology with Omnicell automated dispensing systems in the markets we presently serve, while also expanding our opportunities through MACH4s direct presence in Germany and France.
With the acquisition of MACH4, the expanded Omnicell portfolio now includes innovative solutions that span robotic medication management systems, automated dispensing cabinets and medication adherence technology to meet the unique demands of the companys growing base of customers worldwide to provide services across the continuum of care.
About Omnicell
Since 1992, Omnicell (NASDAQ: OMCL) has been creating new efficiencies to improve patient care, anywhere it is delivered. Omnicell is a leading supplier of comprehensive automation and business analytics software for patient-centric medication and supply management across the entire healthcare continuum from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home.
More than 3,000 customers worldwide have utilized Omnicell Automation and Analytics solutions to increase operational efficiency, reduce errors, deliver actionable intelligence and improve patient safety. Omnicell Medication Adherence solutions, including its MTS Medication Technologies brand, provide innovative medication adherence packaging solutions to help reduce costly hospital readmissions. In addition, these solutions enable approximately 6,000 institutional and retail pharmacies worldwide to maintain high accuracy and quality standards in medication dispensing and administration while optimizing productivity and controlling costs.
For more information about Omnicell, Inc. please visit www.omnicell.com.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
This press release contains forward-looking statements, including, but not limited to, statements related to the closing of the acquisition of MACH4 Pharma Systems and the benefits thereof, including Omnicells ability to utilize MACH4 Pharma Systems presence in Germany and France, the combined companys ability to deliver a comprehensive automated medication management offering, its ability to meet the demands of its worldwide customers and provide services across the continuum of care, and other statements that are not historical facts. These forward-looking statements are based on Omnicells current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to business combination transactions, such as the risk that acquired business will not be integrated successfully or that such integration may be more difficult, time-consuming or costly than expected; risks related to future opportunities and plans for the combined company, including the reaction of the combined companys customers and potential customers, the perceived complementary nature of the combined companys products and solutions, uncertainty of the expected financial performance, market opportunities and results of the combined company following completion of the proposed acquisition; and the possibility that if Omnicell does not achieve the perceived benefits of the acquisition of MACH4 Pharma Systems as rapidly or to the extent anticipated by financial analysts or investors, the market price of Omnicell stock could decline; as well as other risks related Omnicells business, and those other risks detailed from time to time under the caption Risk Factors and elsewhere in Omnicells SEC filings and reports, including in the Annual Report on Form 10-K for the year ended December 31, 2014. Omnicell undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information, future events or changes in its expectations.
OMCL - G
# # #
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Omnicell (OMCL) Announces XT Amplify
- Aclara Announces the Closing of the Transaction with Cap and the Receipt of Initial Payment of Us$9.7M as Part of the US$29.1M Strategic Investment
- Christina Lake Cannabis Provides Bi-Weekly Update on Status of MCTO
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!